• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Alice T. Shaw, MD, PhD

Publications

  • Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S, Pferdekamper AC, Li J, Kasibhatla S, Sun F, Sun X, Hua S, McNamara P, Mahmood S, Lockerman EL, Fujita N, Nishio M, Harris JL, Shaw AT, Engelman JA.The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.Cancer Discovery. 2014 Jun(6):662-73.
    24675041
  • Lovly CM, Shaw AT.Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies.Clin Cancer Res. 2014 May 1;20(9):2249-56.
    24789032
  • Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA.Ceritinib in ALK-rearranged non-small-cell lung cancer.N Engl J Med. 2014 Mar 27;370(13):1189-97.
    24670165
  • Gainor JF, Ou SH, Logan J, Borges LF, Shaw AT.The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer.J Thorac Oncol. 2013 Dec;8(12):1570-3.
    24389440
  • Gainor JF, Shaw AT.Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.J Clin Oncol. 2013 Nov 1;31(31):3987-96.
    24101047
  • Awad MM, Engelman JA, Shaw AT.Acquired resistance to crizotinib from a mutation in CD74-ROS1.N Engl J Med. 2013 Sep 19;369(12):1173.
    24047072
  • Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, Iafrate AJ, Arcila ME, Ladanyi M, Engelman JA, Dias-Santagata D, Shaw AT.ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.Clin Cancer Res. 2013 Aug 1;19(15):4273-81.
    23729361
  • Gainor JF, Shaw AT.Novel targets in non-small cell lung cancer: ROS1 and RET fusions.Oncologist. 2013;18(7):865-75.
    23814043
  • Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA.Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.N Engl J Med. 2013 Jun 20;368(25):2385-94.
    23724913
  • Awad MM, Katayama R, McTigue M, Liu W, Deng YL, Brooun A, Friboulet L, Huang D, Falk MD, Timofeevski S, Wilner KD, Lockerman EL, Khan TM, Mahmood S, Gainor JF, Digumarthy SR, Stone JR, Mino-Kenudson M, Christensen JG, Iafrate AJ, Engelman JA, Shaw AT.Acquired resistance to crizotinib from a mutation in CD74-ROS1.N Engl J Med. 2013 Jun 20;368(25):2395-401.
    23724914
  • Gainor JF, Shaw AT.The new kid on the block: RET in lung cancer.Cancer Discovery. 2013 Jun;3(6):604-6.
    23749525
  • Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez JP, Shaw AT, Doebele RC, He S, Bates RC, Camidge DR, Morris SW, El-Hariry I, Proia DA.Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.Cancer Discovery. 2013 Apr;3(4):430-43.
    23533265
  • Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, Yu M, Chen PI, Morgan B, Trautwein J, Kimura A, Sengupta S, Stott SL, Karabacak NM, Barber TA, Walsh JR, Smith K, Spuhler PS, Sullivan JP, Lee RJ, Ting DT, Luo X, Shaw AT, Bardia A, Sequist LV, Louis DN, Maheswaran S, Kapur R, Haber DA, Toner M.Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.Sci Transl Med. 2013 Apr 3;5(179):179ra47.
    23552373
  • Shaw AT, Engelman JA.ALK in lung cancer: past, present, and future.J Clin Oncol. 2013 Mar 10;31(8):1105-11.
    23401436
  • Jänne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V, Smith P, Smith I, Crinò L.Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.Lancet Oncol. 2013 Jan;14(1):38-47.
    23200175
  • Ramalingam SS, Shaw AT.Hypogonadism related to crizotinib therapy: Implications for patient care.Cancer. 2012 Nov 1;118(21):E1-2.
    22487894
  • Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT.Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.Lancet Oncol. 2012 Oct;13(10):1011-9.
    22954507
  • Goldberg SB, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P, Temel JS, Heist RS, Shaw AT, McCarthy PO, Lynch TJ, Sharma S, Settleman JE, Sequist LV.A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.J Thorac Oncol. 2012 Oct;7(10):1602-8.
    22878749
  • Crystal AS, Shaw AT.Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer?.Clin Cancer Res. 2012 Sep 1;18(17):4479-81.
    22912388
  • Bergethon K, Shaw AT, Ignatius Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ.ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers.J Clin Oncol. 2012 Mar 10;30(8):863-70.
    22215748
  • Shaw AT, Solomon B.Targeting Anaplastic Lymphoma Kinase in Lung Cancer.Clin Cancer Res. 2011 Apr 5.
    21288922
  • Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA.Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors.Sci Transl Med. 2011 Mar 23;3(75):75ra26.
    21430269
  • Neal JW, Shaw AT.One allele's loss is another's gain: alterations of NKX2-8 in non-small cell lung cancer.Clin Cancer Res. 2011 Feb 15;17(4):638-9.
    21163872
  • Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, Bang YJ, Kwak EL, Shaw AT, Salgia R, Maki RG, Clark JW, Wilner KD, Iafrate AJ.Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.J Thorac Oncol. 2010 Dec;5(12):2044-6.
    21102269
  • Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ.Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.N Engl J Med. 2010 Oct 28;363(18):1693-703.
    20979469
  • Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ.Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK.J Clin Oncol. 2009 Sep 10;27(26):4247-53.
    19667264
  • Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, Lynch T, Johnson BE, Iafrate AJ, Chirieac LR.Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.Clin Cancer Res. 2009 Aug 15;15(16):5216-23.
    19671850
  • Lynch TJ Jr,Blumenschein GR Jr,Engelman JA,Espinoza-Delgado I,Govindan R,Hanke J,Hanna NH,Heymach JV,Hirsch FR,Janne PA,Lilenbaum RC,Natale RB,Riely GJ,Sequist LV,Shapiro GI,Shaw A,Shepherd FA,Socinski M,Sorensen AG,Wakelee HA,Weitzman A.Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S107-12.
    18520291
  • Shaw AT, Meissner A, Dowdle JA, Crowley D, Magendantz M, Ouyang C, Parisi T, Rajagopal J, Blank LJ, Bronson RT, Stone JR, Tuveson DA, Jaenisch R, Jacks T.Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis.Genes Dev. 2007 Mar 15;21(6):694-707.
    17369402
  • Kim CF, Jackson EL, Kirsch DG, Grimm J, Shaw AT, Lane K, Kissil J, Olive KP, Sweet-Cordero A, Weissleder R, Jacks T.Mouse models of human non-small-cell lung cancer: raising the bar.Cold Spring Harb Symp Quant Biol. 2005;70:241-50. Review.
    16869760
  • Shaw AT, Kirsch DG, Jacks T.Future of early detection of lung cancer: the role of mouse models.Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):4999s-5003s.
    16000603
  • Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, Mercer KL, Grochow R, Hock H, Crowley D, Hingorani SR, Zaks T, King C, Jacobetz MA, Wang L, Bronson RT, Orkin SH, DePinho RA, Jacks T.Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.Cancer Cell. 2004 Apr;5(4):375-87.
    15093544
  • Tsang AP, Fujiwara Y, Hom DB, Orkin SH.Failure of megakaryopoiesis and arrested erythropoiesis in mice lacking the GATA-1 transcriptional cofactor FOG.Genes Dev. 1998 Apr 15;12(8):1176-88.
    9553047
  • Tsang AP, Visvader JE, Turner CA, Fujiwara Y, Yu C, Weiss MJ, Crossley M, Orkin SH.FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation.Cell. 1997 Jul 11;90(1):109-19.
    9230307
  • Crossley M, Tsang AP, Bieker JJ, Orkin SH.Regulation of the erythroid Kruppel-like factor (EKLF) gene promoter by the erythroid transcription factor GATA-1.J Biol Chem. 1994 Jun 3;269(22):15440-4.
    8195185
  • Protic M, Hirschfeld S, Tsang AP, Wagner M, Dixon K, Levine AS.Induction of a novel damage-specific DNA binding protein correlates with enhanced DNA repair in primate cells.Mol Toxicol. 1989 Oct-Dec;2(4):255-70.
    2518795